Penumbra, Inc. Stock News
$279.79
1.19%
yesterday
NYSE,
Nov 20, 10:00 pm CET
Index
Industry
Penumbra, Inc. Stock News
Neutral
PRNewsWire
●
one day ago
ALAMEDA, Calif. , Nov. 19, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025.
Positive
Investors Business Daily
●
15 days ago
Penumbra stock skyrocketed Thursday after the medtech company beat third-quarter expectations on the back of its blood-clot-removing tech.
Neutral
Seeking Alpha
●
15 days ago
Penumbra, Inc. ( PEN ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Cecilia Furlong Adam Elsesser - Co-Founder, Chairman & CEO Shruthi Narayan - President Maggie Yuen - Chief Financial Officer Conference Call Participants Travis Steed - BofA Securities, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Larry Biegelsen - Wells Fargo Securities, L...
Neutral
PRNewsWire
●
15 days ago
ALAMEDA, Calif. , Nov. 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025.
Neutral
PRNewsWire
●
17 days ago
The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to those who received only anticoagulation Results of STORM-PE demonstrating superior efficacy of CAVT with anticoagulati...
Neutral
PRNewsWire
●
25 days ago
ALAMEDA, Calif. , Oct. 27, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that the use of mechanical thrombectomy, specifically computer assisted vacuum thrombectomy (CAVT™), with anticoagulation achieved superior reduction in right heart strain compared to anticoagulation therapy alone in patients wi...
Neutral
Seeking Alpha
●
25 days ago
Penumbra, Inc. (NYSE:PEN ) Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 October 26, 2025 7:00 PM EDT Company Participants Adam Elsesser - Co-Founder, Chairman & CEO Shruthi Narayan - President James Benenati - Chief Medical Officer Conference Call Participants Robert Lookstein William Plovanic - Canaccord Genuity Corp., Research Division Rachel Rosovsky Stavros Konstantinides...
Positive
Investors Business Daily
●
25 days ago
Penumbra unveiled the results of a study on Sunday showing its device is superior to blood thinners in pulmonary embolism patients.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
